Table 1.

Patient characteristics: tumor biological features and therapy regimens.

Pt	Age at First Diagnosis	Biopsy and staging	NAC	Surgery and Restaging	AC, RT, HT	DFS	Site of 1st Recurrence	1st-Line Therapy	PFS I	2nd-Line Therapy	PFS II
PT#51	2013 40 years	/	No	Ductal BC pT2, G2 pN3a ER: 40% PgR: 40% Ki67:8%	EC (4 cycles) + T (12 cycles) + RT + LHRHa and Tam	4 ys	Bones	CDK4/6 Inhibitors + AI	22 ms	Alpelisib + fulvestrant	NA
Pt#55	2004 43 years	Ductal BC cT4b cN1 ER: 75% PgR: 5% Ki67: 24%	E + C + D (6 cycles)	Ductal BC ypT1c, G2 pN1a ER: 15% PgR: 0% Ki67: 25%	C + M + F (3 cycles) + RT + Tam for 2 ys, then AI for 3 ys	8 ys	Bones	CDK4/6 Inhibitors + AI	12 ms	Alpelisib + fulvestrant	7 ms
Pt#60	2018 65 years	Ductal BC M1 ER: 90% PgR: 70%Ki67: 20%	No	/	/	/	Bones	CDK4/6 Inhibitors + AI	21 ms	Alpelisib + fulvestrant	7 ms
Pt#61	2015 41 years	Ductal BC ER: 96% PgR: 86% Ki67: 18%	EC (4 cycles) + T (12 cycles)	Ductal BC ypT1c, G2 pN1a ER: 93% PgR: 16% KI67: 6%	RT + LHRHa and AI	4 ys	Bones, nodes, liver	CDK4/6 Inhibitors + fulvestrant	5 ms	Alpelisib + fulvestrant	3 ms

Legend: ER: estrogen receptor; PgR: progesterone receptor; NAC: neoadjuvant therapy; AC: adjuvant chemotherapy, RT: radiotherapy; HT: hormone therapy; DFS: disease-free survival; PSF: progression-free survival; EC: epirubicin and cyclophosphamide; T: paclitaxel; C: capecitabine; D: docetaxel; Tam: tamoxifen; M: methotrexate; F,: fluorouracil; ms: months; ys: years; AI: aromatase inhibitors; LHRHa: luteinizing hormone-releasing hormone analog; NA: not available.